Tools and Links

Pediatrics
April 2016, VOLUME 137 / ISSUE 4
Review Article

Interventions To Prevent Retinopathy of Prematurity: A Meta-analysis

Jennifer L. Fang, Atsushi Sorita, William A. Carey, Christopher E. Colby, M. Hassan Murad, Fares Alahdab
Download PDF

Abstract

CONTEXT: The effectiveness of many interventions aimed at reducing the risk of retinopathy has not been well established.

OBJECTIVE: To estimate the effectiveness of nutritional interventions, oxygen saturation targeting, blood transfusion management, and infection prevention on the incidence of retinopathy of prematurity (ROP).

DATA SOURCES: A comprehensive search of several databases was conducted, including Medline, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus through March 2014.

STUDY SELECTION: We included studies that evaluated nutritional interventions, management of supplemental oxygen, blood transfusions, or infection reduction and reported the incidence of ROP and mortality in neonates born at <32 weeks.

DATA EXTRACTION: We extracted patient characteristics, interventions, and risk of bias indicators. Outcomes of interest were any stage ROP, severe ROP or ROP requiring treatment, and mortality.

RESULTS: We identified 67 studies enrolling 21 819 infants. Lower oxygen saturation targets reduced the risk of developing any stage ROP (relative risk [RR] 0.86, 95% confidence interval [CI], 0.77–0.97) and severe ROP or ROP requiring intervention (RR 0.58, 95% CI, 0.45–0.74) but increased mortality (RR 1.15, 95% CI, 1.04–1.29). Aggressive parenteral nutrition reduced the risk of any stage ROP but not severe ROP. Supplementation of vitamin A, E, or inositol and breast milk feeding were beneficial but only in observational studies. Use of transfusion guidelines, erythropoietin, and antifungal agents were not beneficial.

LIMITATIONS: Results of observational studies were not replicated in randomized trials. Interventions were heterogeneous across studies.

CONCLUSIONS: At the present time, there are no safe interventions supported with high quality evidence to prevent severe ROP.

  • Abbreviations:
    CI —
    confidence interval
    EPO —
    erythropoietin
    PN —
    parenteral nutrition
    PRBC —
    packed red blood cell
    RCT —
    randomized controlled trial
    ROP —
    retinopathy of prematurity
    RR —
    relative risk
    VLBW —
    very low birth weight

    • Retinopathy of prematurity (ROP) is a disorder of the developing retina in preterm infants and is a leading cause of childhood blindness.1 ROP primarily affects neonates born at <32 weeks gestational age, with the risk and severity of ROP increasing with decreasing gestational age. Depending on the population studied, 20% to 50% of very low birth weight (VLBW, birth weight <1500 g) infants will develop ROP, with 4% to 19% having severe ROP (stages 3–5).1,2

    Although incompletely understood, the pathogenesis of ROP involves multiple signaling factors and has been characterized by 2 phases.3 The first phase begins after preterm birth and involves growth cessation of the retinal vasculature. Then at ∼32 weeks postmenstrual age, retinal neovascularization begins, marking the initiation of phase 2. Although preterm delivery is the primary risk factor for the development of ROP, multiple other modifiable clinical factors have been associated with an increased risk of ROP. These correlate well with the current understanding of ROP pathogenesis and include poor postnatal weight gain in the first 6 weeks of life,4,5 hyperoxia,6–8 exposure to packed red blood cell (PRBC) transfusions,9,10 and late onset sepsis.11–13

    The objective of this meta-analysis was to study the effect and magnitude of the benefit of multiple interventions aimed at the prevention of ROP in preterm neonates <32 weeks gestational age. Four categories of interventions were selected based on the current understanding of ROP pathophysiology and included: (1) postnatal nutrition, (2) management of supplemental oxygen, (3) PRBC transfusions, and (4) infection reduction.

    Methods

    Evidence Acquisition

    This systematic review is reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement.14

    Data Sources and Search Strategy

    A comprehensive search of several databases was conducted from each database’s earliest inception to March 2014, any language, in infants. The databases included Ovid Medline In-Process & Other Non-Indexed Citations, Ovid Medline, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by an experienced librarian with input from the study’s principal investigator. Controlled vocabulary supplemented with keywords was used to search for comparative studies of interventions for the prevention of ROP. The actual strategy is available in the Supplemental Information. To identify additional candidate studies, we reviewed reference lists from eligible studies.

    Selection of Studies

    Initial screening of the identified studies was performed by 4 independent reviewers working in duplicates based on the titles and abstracts, taking into consideration the inclusion criteria. After removing irrelevant and non-original studies, full-text screening was then performed to assess eligibility for final inclusion. Discrepancies were resolved through discussion and consensus.

    We used a list of inclusion criteria set a priori for the initial and full article screening. We sought studies that included preterm infants <32 weeks gestational age who were cared for in a NICU. Interventions of interest comprised 4 main categories including postnatal nutritional interventions, management of supplemental oxygen, PRBC transfusions, and interventions aimed at reducing infections. Main outcomes of interest were incidence of any stage ROP, severe ROP (defined as stage 3–5), and ROP requiring bevacizumab or surgical treatment. Because the interventions of interest could potentially impact mortality, we also collected data on in-hospital any-cause mortality.

    We included comparative original studies (randomized or observational) and excluded single arm studies. Both randomized and observational studies were included in the analysis so as to capture all existing evidence on this question. When ≥2 randomized controlled trials (RCTs) were available, a planned subgroup analysis of only the RCTs was performed. We could then determine whether the outcome effect persisted when the lesser quality evidence was excluded from the analysis.

    Data Extraction

    Reviewers extracted data independently from the included studies in duplicates, using a standardized, piloted, Web-based form that was developed based on the protocol. Data extracted included: demographics of participants, patient inclusion criteria, study design, intervention details, and outcomes of interest. For all outcomes, we extracted dichotomous data whenever available including number of patients with any stage ROP, severe ROP, ROP requiring treatment, and in-hospital mortality, as well as total numbers in each arm. When this data were not available, we used the effect measures reported by the individual studies (relative risks, odds ratios) along with the corresponding 95% confidence intervals (CIs) for the meta-analysis. Outcome data were extracted at the last follow-up reported. All disagreements or differences in extracted data were resolved by consensus.

    Methodological Quality and Risk of Bias Assessment

    Randomized trials were evaluated using the Cochrane risk of bias assessment tool.15 For every study, the following was determined: how the randomization sequence was generated, whether allocation was concealed, who was blinded, the degree of loss of follow-up, and the nature of funding sources. Observational studies were evaluated using the Newcastle–Ottawa tool.16 This tool included the assessment of how the subjects represented the population of interest, how the comparative group was selected, how outcome was assessed, and the length and adequacy of follow-up when applicable. All discrepancies were resolved by a third reviewer with expertise in methodology.

    Statistical Analysis

    The reviewers extracted the contingency table data from the included studies to calculate the relative risks. We conducted a meta-analysis to pool relative risks using the random effect model to account for heterogeneity between studies as well as within-study variability.17 We used the I2 statistic to estimate the percentage of total between-study variation due to heterogeneity rather than chance (ranging from 0% to 100%).18,19 I2 values of 25%, 50%, and 75% are thought to represent low, moderate, and high heterogeneity, respectively. Statistical analyses were conducted through OpenMeta.20 All values are two-tailed and P < .05 was set as the threshold for statistical significance.

    Results

    Study Selection

    The flow diagram for study selection can be seen in Fig 1. From the database search and other sources, a total of 1479 records were identified for screening. Eighty-five studies were included in the qualitative analysis. We eventually identified 67 studies that provided quantitative data and they were included in the meta-analysis.

    FIGURE 1
    FIGURE 1

    PRISMA flow diagram for study selection. Reprinted with permission from Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement. PLoS Med. 2009:6(6):e1000097.

    Study Characteristics

    Twenty-seven studies on postnatal nutrition were included in the meta-analysis. These were further categorized into studies on the effect of human milk,21–25 early aggressive parenteral nutrition (PN),26–29 fish oil–based lipid emulsion,30,31 and dietary supplementation with vitamin A,32–35 vitamin E,36–43 inositol,44,45 and lutein.46,47 There were 17 studies on the management of supplemental oxygen, all of which addressed the effect of oxygen saturation targeting.48–64 A total of 18 studies on the effect of PRBC transfusions were analyzed. Five reports studied the effect of transfusion guidelines,10,65–68 and the other 13 studied the effect of exogenous erythropoietin (EPO) on the risk of ROP.69–81 All 5 studies of infection prevention pertained to the effect of fluconazole prophylaxis.82–86

    Risk of Bias Assessment

    The risk of bias evaluation of the included studies is summarized in Figs 2 and 3. For the 85 studies included in qualitative analysis, 55 were RCTs and 30 were observational studies. The included RCTs showed an overall medium risk of bias. Almost half of them were unblinded. The risk of bias assessment of the included observational studies showed low to medium risk of bias. These studies exhibited risk of bias in areas such as outcome assessment, follow-up sufficiency, and length of follow-up.

    FIGURE 2
    FIGURE 2

    Risk of bias assessment for included RCTs. aUnclear or industry funding are designated in red.

    FIGURE 3
    FIGURE 3

    Risk of bias assessment for included observational studies. COI, conflict of interest; FU, follow-up.

    Synthesis of Results

    Postnatal Nutritional Interventions

    Increased use of human milk for enteral feeds did not reduce the risk of any stage ROP. However, meta-analysis of 2 observational studies demonstrated a significant 60% reduction in severe ROP with increased human milk exposure (relative risk [RR] 0.39, 95% CI, 0.17–0.92;Fig 4, Table 1). Additionally, analysis of 2 studies on the use of an exclusive human milk–based diet suggested a reduced risk of death before discharge (RR 0.27, 95% CI, 0.08–0.96; Fig 4, Table 1).

    FIGURE 4
    FIGURE 4

    Forest plots for significant analyses of postnatal nutritional interventions. Ctrl, control group; Ev, events; Trt, treatment group.

    View this table:
    TABLE 1

    Meta-analysis of Postnatal Nutritional Interventions

    When all study designs of early, aggressive PN were analyzed for effect on any stage ROP, there was no significant difference. However, analysis of the 2 RCTs on early, aggressive PN demonstrated a 78% risk reduction in any stage ROP when compared with more conservatively prescribed PN (RR 0.22, 95% CI, 0.09–0.55, Table 1, Fig 4). Aggressive PN did not have an effect on severe ROP or mortality. There was no change in the incidence of any stage ROP or severe ROP with use of a fish oil–based lipid emulsion for PN (Table 1).

    Multiple nutritional supplements were also analyzed for their effects on ROP (Table 1). Vitamin A supplementation reduced the risk of any stage ROP by 33% (RR 0.67, 95% CI, 0.46–0.97; Fig 4, Table 1), but it had no effect on the incidence of severe ROP or mortality. Supplementation with vitamin E did not affect rates of any stage ROP. When analyzing both RCTs and observational studies, vitamin E supplementation was found to reduce the risk of developing severe ROP by 51% (RR 0.49, 95% CI, 0.24–0.98; Fig 4, Table 1). However, when the single observational study was removed and only the RCTs were analyzed, there was no longer a significant reduction in the risk of severe ROP (RR 0.52, 95% CI, 0.23–1.14). The 2 studies on lutein supplementation revealed no effect on the risk of any stage ROP, severe ROP, or death before discharge. The incidence of any stage ROP was not impacted by inositol supplementation. However, the 2 studies of inositol administration either as an intravenous medication or via formula feeds demonstrated a significantly reduced overall relative risk of severe ROP when compared with controls with no or minimal inositol exposure (RR 0.14, 95% CI, 0.03–0.69; Fig 4, Table 1).

    Management of supplemental oxygen

    Studies on the management of supplemental oxygen were primarily focused on oxygen saturation targeting (Table 2). Meta-analysis revealed that lower oxygen saturation targets, as defined by each study, resulted in a 14% reduction in the risk of developing any stage ROP (RR 0.86, 95% CI, 0.77–0.97; Fig 5, Table 2).

    View this table:
    TABLE 2

    Meta-analysis of Oxygen Saturation Targeting

    FIGURE 5
    FIGURE 5

    Forest plots for significant analyses of oxygen saturation targeting. Ctrl, control group; EV, events; Trt, treatment.

    Fifteen studies of oxygen saturation targeting were analyzed for effect on severe ROP rates. When compared with higher oxygen saturation targets, lower oxygen saturation targets were associated with a 42% reduced risk of severe ROP or ROP requiring surgery (RR 0.58, 95% CI, 0.46–0.74; Fig 5, Table 2). When observational studies were excluded, analysis of the 4 RCTs demonstrated a nearly significant overall reduced risk of severe ROP for infants with oxygen saturation targets of 85% to 89% when compared with those with targets of 91% to 95% (RR of 0.72, 95% CI, 0.51–1.00; Fig 5, Table 2).

    Analysis of 8 studies on oxygen saturation targeting revealed lower oxygen saturation targets (as defined by each study) increased the risk of death before discharge by 15% (RR 1.15, 95% CI, 1.04–1.29; Fig 5, Table 2). This finding remained significant when the 4 RCTs comparing oxygen saturation targets of 85% to 89% to targets of 91% to 95% were analyzed (RR 1.17, 95% CI, 1.03–1.32; Fig 5, Table 2).

    Management of Red Blood Cell Transfusions

    Studies on the management of PRBC transfusions focused on 2 primary interventions: the use of hemoglobin transfusion guidelines and administration of EPO (Table 3). The use of more restrictive, hemoglobin-based PRBC transfusion guidelines did not significantly affect the risk of any stage ROP (RR 0.99, 95% CI, 0.77–1.25), severe ROP (RR 1.02, 95% CI, 0.68–1.53 for RCTs only), or death before discharge (RR 1.27, 95% CI, 0.88–1.84) when compared with standard care or more liberal guidelines. The administration of EPO did not influence the risk of any stage ROP (RR 1.09, 95% CI, 0.91–1.30), severe ROP (RR 1.13, 95% CI, 0.77–1.64), or mortality (RR 0.94, 95% CI, 0.69–1.29) when all study designs were analyzed. This held true when the meta-analysis was limited to only RCTs. Similarly, subgroup analysis based on the timing of the first dose of EPO (early EPO defined as first dose given at <8 days of life and late EPO defined as first dose given at >8 days of life) failed to demonstrate an impact on any of the outcomes analyzed.

    View this table:
    TABLE 3

    Meta-analysis of Management of PRBC Transfusions

    Interventions for Infection Reduction

    There were 9 studies on the effect of infection reduction interventions on rates of ROP; however, only those on fluconazole prophylaxis for the prevention of fungal infection had a sufficient number of studies to allow for quantitative analysis (Table 4). No studies reported rates of any stage ROP. Meta-analysis of 4 studies demonstrated no significant effect of fluconazole prophylaxis on the risk of developing severe ROP or ROP requiring surgery (RR 0.82, 95% CI, 0.62–1.10). Fluconazole prophylaxis did not affect rates of death before hospital discharge (RR 0.85, 95% CI, 0.63–1.14). Findings were similar when only the 4 RCTs were analyzed (RR 0.83, 95% CI, 0.60–1.15).

    View this table:
    TABLE 4

    Meta-analysis of Infection Prevention

    Discussion

    Summary of Evidence

    Although there are few, focused systematic reviews on the prevention of ROP,87–89 this is the first comprehensive meta-analysis of interventions aimed at multiple modifiable risk factors thought to be associated with an increased incidence of ROP. Our review revealed multiple subcategories of postnatal nutritional interventions. Meta-analysis of 2 cohort studies22,25 on the effect of breast milk versus formula feeds found a 60% reduction in the risk of severe ROP. This favorable finding was complicated by the need to categorize intervention and control groups as only or mainly breast milk fed compared with only or mainly infant formula fed, respectively. This classification was necessary because of the variability between studies in reporting enteral feed type, volume, exclusivity, duration, etc. The intervention group in the study by Hylander et al22 received 20% to 100% human milk feeding whereas the control group was exclusively formula fed. Comparatively, the Maayan-Metzger et al25 intervention group received at least 5 of 8 meals as human milk during the first month of life, whereas the control group received ≤3 human milk feeds. We also found that an exclusive human milk diet may have a favorable effect on the risk of mortality before discharge for preterm infants. The 2 RCTs of exclusive human milk feedings that used a human milk–based fortifier23,24 demonstrated a significant overall reduced relative risk of mortality equal to 0.27.

    The 2 RCTs of early, aggressive PN26,29 demonstrated a significant 80% reduction in any stage ROP. Although the trials were analyzed together because both studied early, aggressive PN, the exact PN strategy was different between the 2 studies. Can et al26 studied the effect of both increased early amino acid and fat emulsion administration. Drenckpohl et al29, on the other hand, studied the effect of only increased early fat emulsion (initial amino acid delivery was 3 g/kg per day in both experimental and control groups with a goal of 3.5 g/kg per day). However, evidence suggests that early, aggressive PN is safe,90–92 so the potential benefit of this intervention on reducing rates of ROP likely outweighs any known risks.

    Vitamin A supplementation via intramuscular injection reduced the rate of any stage ROP by 30%. However, the dosing regimen used in the 3 studies analyzed32,34,35 was variable, making clinical application challenging. Additionally, vitamin A injection may not be a reliable means of ROP prevention given that it was not commercially available during a recent 4-year shortage (late 2010 to July 2014). Although it is again on the market, the estimated cost of injectable vitamin A has increased substantially from $18 per vial before the shortage to $1100 per vial after the shortage (K.K. Graner, RPh., personal communication, 2015), arguably making this a cost-prohibitive ROP prevention strategy.

    Analysis of vitamin E and inositol suggested that these supplements may reduce the risk of severe ROP. When all study types were evaluated, vitamin E supplementation36,37,39–43 reduced the risk of severe ROP by 50%. However, this positive effect was no longer significant when the single cohort study40 was removed and only the RCTs were analyzed. In addition, 3 of the studies used intravenous vitamin E. Caution may be warranted when prescribing intravenous vitamin E to preterm infants because previous evidence has raised concern for an increased risk of sepsis with this route of administration.93

    Inositol is a nonglucose carbohydrate that may play an important role in early development and is involved in cell signaling, neuronal development, and pulmonary surfactant production.94 For reference, the average concentration of inositol in preterm milk is ∼1350 μmol/L (or 240 mg/L).95 The commonly prescribed preterm infant formulas currently in use contain 280 to 350 mg/L of inositol.96–98 Analysis of the single cohort study44 and 1 RCT45 of inositol supplementation revealed a significantly reduced overall relative risk of severe ROP. In the first study, Friedman et al44 studied the effect of a high inositol infant formula (2500 μmol/L or 450 mg/L) on rates of severe ROP. The second study by Hallman et al45 supplemented neonates in the intervention group with intravenous inositol (80 mg/kg per day for the first 5 days of life). Although this limited meta-analysis of 2 studies suggests that inositol could positively affect rates of severe ROP, additional data should be forthcoming in the next 2 to 5 years. The Eunice Kennedy Shriver National Institute of Child Health and Human Development is currently recruiting participants for a phase 3, randomized, placebo-controlled study to determine the effectiveness of myo-inositol injection on increasing the incidence of survival without severe ROP in preterm neonates <28 weeks gestation (www.clinicaltrials.gov, identifier NCT01954082).99

    Our quantitative meta-analysis of supplemental oxygen management focused on the effect of oxygen saturation targets on rates of ROP. Lower oxygen saturation targets, as defined by each study, reduced the rate of any stage ROP by nearly 15% when all study designs were analyzed.48,50, 52,54, 56,57,60,61 Interestingly, studies in the United States50,52,56, 57,60,61 showed a significant reduction in any stage ROP with lower oxygen saturation targets (RR 0.78, 95% CI, 0.68–0.88), whereas this effect was not significant in other countries.48,54

    Fifteen cohort studies and RCTs studying oxygen saturation targeting reported rates of severe ROP or ROP requiring intervention.48,49,51, 53–64 By incorporating the cohort studies into the meta-analysis, >8000 preterm neonates were included. Approximately half of the preterm neonates were enrolled in a randomized, controlled trial.48,53,63,64 The remaining 46% were part of a cohort study that frequently involved investigating ROP outcomes after a change in clinical management of supplemental oxygen.49,51,54–62 In these studies, the definition of “lower oxygen saturation target” varied from a low of 70% to 90%62 to a high of 90% to 96%.58 The definition of “higher oxygen saturation target” ranged from a low of 88% to 96%49 to a high of 95% to 100%.56 Based on our meta-analysis, the risk of severe ROP or ROP requiring intervention was reduced by 40% using lower oxygen saturation targets as defined by each study.

    However, this approach to oxygen management appears to be associated with undesirable effects on mortality before hospital discharge. When all study types were analyzed, we found an unacceptable 15% increased risk of mortality before discharge with lower oxygen saturation targets. Interestingly, 949–52,54,55,58,60,62 of the 13 cohort studies did not report in-hospital mortality rates as an additional outcome. Analysis limited to the 4 RCTs48,53,63,64 again demonstrated a 17% increased risk of in-hospital mortality for those infants with a lower oxygen saturation target (85–90%) when compared with those with a higher oxygen saturation target (91–95%). Our overall relative risk of in-hospital mortality (RR 1.17) is lower than that reported in the NEOPROM collaborative study8 (RR 1.41, 95% CI, 1.14–1.74). In the NEOPROM study, only the infants monitored with the revised oximeter calibration algorithm were included in their death at discharge analysis. These infants may have spent more time in the intended lower oxygen saturation range resulting in a greater increased risk of death.

    We also evaluated ROP outcomes for interventions aimed at managing PRBC transfusions: primarily the use of hemoglobin transfusion guidelines and administration of EPO. However, we found no significant impact of either intervention on rates of any stage ROP, severe ROP, or ROP requiring intervention. Although our meta-analysis includes additional recently available studies, the findings are similar to previously published Cochrane reviews.100–102

    There is very little literature published on reducing the risk of infection in preterm neonates and its effect on the incidence of ROP. Although there are single studies of interventions to prevent infection that also report ROP outcomes,103–105 only those studying fluconazole prophylaxis had sufficient numbers for quantitative analysis. Despite a reduced risk of invasive fungal infection, fluconazole prophylaxis has no significant effect on the risk of developing severe ROP.

    Limitations

    The greatest limitation of this meta-analysis is the overall absence of large, well-designed clinical studies in the literature. Approximately 75 000 neonates are born at <32 completed weeks of gestation each year in the United States,106 and ROP is one of the key morbidities that can lead to long-term neurodevelopmental impairment in these infants. The results of this study suggest that there is a significant need for enhanced translational and clinical research to better understand how ROP can safely be prevented in very preterm neonates.

    Among the studies included in this meta-analysis, the format for reporting ROP outcomes was highly variable (eg, by stage, type, prethreshold/threshold, need for surgery, etc). To address this issue, we analyzed ROP outcomes using 2 categories: (1) presence of any stage ROP, and (2) ROP that was likely to result in an unfavorable visual outcome. An undesirable retinal outcome included patients with severe ROP (stage ≥3), type 1 threshold ROP, or ROP requiring medical or surgical intervention. If a single study reported undesirable retinal outcomes in multiple formats, the rate of severe ROP was used to provide increased sensitivity and similarity between articles. The use of common standards for ROP outcomes research is needed.

    This meta-analysis was also limited by the heterogeneity of interventions even within categories as previously described (eg, variation in vitamin and medication dosages/regimens, parenteral and enteral feeding strategies, definition of oxygen saturation targets, hemoglobin transfusion guidelines, etc). However, study characteristics were thoughtfully reviewed before the meta-analyses in an effort to provide a meaningful synthesis of the current evidence on the prevention of ROP to guide care of the preterm infant.

    Conclusions

    The results of this meta-analysis suggest that vitamin A supplementation and early, aggressive PN may reduce any stage ROP in preterm infants. Risk of severe ROP or ROP requiring surgery may be reduced with breast milk feedings, vitamin E supplementation, and inositol therapy. Although lower oxygen saturation targets reduce the risk of both any stage and severe ROP, this approach to oxygen management should be approached with caution given concerns about potential adverse effects on mortality before discharge. Transfusion guidelines, use of early or late EPO, and fluconazole prophylaxis do not affect the risk of developing ROP. Continued work is needed to identify additional practice management strategies and medical therapies for the prevention of ROP in at-risk preterm neonates.

    Acknowledgments

    We thank the Mayo Clinic Quality Academy and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery for supporting this study.

    Footnotes

      • Accepted January 5, 2016.
    • Address correspondence to Jennifer Fang, MD, Division of Neonatal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905. E-mail: fang.jennifer{at}mayo.edu

    • FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

    • FUNDING: No external funding.

    • POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

    References

    1. ↵
      1. Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists
      . Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189–195pmid:23277315
      OpenUrlAbstract/FREE Full Text
    2. ↵
      1. Holmström G,
      2. Larsson E
      . Outcome of retinopathy of prematurity. Clin Perinatol. 2013;40(2):311–321pmid:23719312
      OpenUrlCrossRefPubMed
    3. ↵
      1. Hellström A,
      2. Smith LE,
      3. Dammann O
      . Retinopathy of prematurity. Lancet. 2013;382(9902):1445–1457pmid:23782686
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      1. Hellström A,
      2. Hård AL,
      3. Engström E, et al
      . Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics. 2009;123(4). Available at: www.pediatrics.org/cgi/content/full/123/4/e638pmid:19289449
    5. ↵
      1. Löfqvist C,
      2. Andersson E,
      3. Sigurdsson J, et al
      . Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006;124(12):1711–1718pmid:17159030
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      1. Campbell K
      . Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust. 1951;2(2):48–50pmid:14874698
      OpenUrlPubMed
      1. Patz A,
      2. Hoeck LE,
      3. De La Cruz E
      . Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol. 1952;35(9):1248–1253pmid:12976495
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      1. Saugstad OD,
      2. Aune D
      . Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. Neonatology. 2014;105(1):55–63pmid:24247112
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      1. Hesse L,
      2. Eberl W,
      3. Schlaud M,
      4. Poets CF
      . Blood transfusion. Iron load and retinopathy of prematurity. Eur J Pediatr. 1997;156(6):465–470pmid:9208245
      OpenUrlCrossRefPubMedWeb of Science
    10. ↵
      1. Del Vecchio A,
      2. Henry E,
      3. D’Amato G, et al
      . Instituting a program to reduce the erythrocyte transfusion rate was accompanied by reductions in the incidence of bronchopulmonary dysplasia, retinopathy of prematurity and necrotizing enterocolitis. J Matern Fetal Neonatal Med. 2013;26(suppl 2):77–79pmid:24059559
      OpenUrlCrossRefPubMed
    11. ↵
      1. Mittal M,
      2. Dhanireddy R,
      3. Higgins RD
      . Candida sepsis and association with retinopathy of prematurity. Pediatrics. 1998;101(4 pt 1):654–657pmid:9521951
      OpenUrlAbstract/FREE Full Text
      1. Manzoni P,
      2. Maestri A,
      3. Leonessa M,
      4. Mostert M,
      5. Farina D,
      6. Gomirato G
      . Fungal and bacterial sepsis and threshold ROP in preterm very low birth weight neonates. J Perinatol. 2006;26(1):23–30pmid:16355104
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      1. Tolsma KW,
      2. Allred EN,
      3. Chen ML,
      4. Duker J,
      5. Leviton A,
      6. Dammann O
      . Neonatal bacteremia and retinopathy of prematurity: the ELGAN study. Arch Ophthalmol. 2011;129(12):1555–1563pmid:22159674
      OpenUrlCrossRefPubMedWeb of Science
    14. ↵
      1. Moher D,
      2. Liberati A,
      3. Tetzlaff J,
      4. Altman DG; PRISMA Group
      . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. Available at: http://www.bmj.com/content/339/bmj.b2535.longpmid:19622551
      OpenUrlFREE Full Text
    15. ↵
      1. Higgins, JPT,
      2. Altman D,
      3. Sterne, JAC
      Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: John Wiley & Sons, Ltd; 2008
    16. ↵
      1. Wells GASB,
      2. O’Connell D,
      3. Peterson J,
      4. Welch V,
      5. Losos M,
      6. Tugwell P
      . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed June 1, 2014
    17. ↵
      1. DerSimonian R,
      2. Laird N
      . Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188pmid:3802833
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      1. Higgins JP,
      2. Thompson SG
      . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558pmid:12111919
      OpenUrlCrossRefPubMedWeb of Science
    19. ↵
      1. Higgins JP,
      2. Thompson SG,
      3. Deeks JJ,
      4. Altman DG
      . Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560pmid:12958120
      OpenUrlFREE Full Text
    20. ↵
      1. Wallace BC,
      2. Dahabrah IJ,
      3. Trikalinos TA,
      4. Lau J,
      5. Trow P,
      6. Schmid CH
      . Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49(5):1–15
      OpenUrl
    21. ↵
      1. Furman L,
      2. Taylor G,
      3. Minich N,
      4. Hack M
      . The effect of maternal milk on neonatal morbidity of very low-birth-weight infants. Arch Pediatr Adolesc Med. 2003;157(1):66–71pmid:12517197
      OpenUrlCrossRefPubMedWeb of Science
    22. ↵
      1. Hylander MA,
      2. Strobino DM,
      3. Pezzullo JC,
      4. Dhanireddy R
      . Association of human milk feedings with a reduction in retinopathy of prematurity among very low birthweight infants. J Perinatol. 2001;21(6):356–362pmid:11593368
      OpenUrlCrossRefPubMed
    23. ↵
      1. Sullivan S,
      2. Schanler RJ,
      3. Kim JH, et al
      . An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. J Pediatr. 2010;156(4):562–567.e1pmid:20036378
      OpenUrlCrossRefPubMedWeb of Science
    24. ↵
      1. Cristofalo EA,
      2. Schanler RJ,
      3. Blanco CL, et al
      . Randomized trial of exclusive human milk versus preterm formula diets in extremely premature infants. J Pediatr. 2013;163 (6):1592–1595.e1
      OpenUrl
    25. ↵
      1. Maayan-Metzger A,
      2. Avivi S,
      3. Schushan-Eisen I,
      4. Kuint J
      . Human milk versus formula feeding among preterm infants: short-term outcomes. Am J Perinatol. 2012;29(2):121–126pmid:22094917
      OpenUrlCrossRefPubMed
    26. ↵
      1. Can E,
      2. Bülbül A,
      3. Uslu S,
      4. Bolat F,
      5. Cömert S,
      6. Nuhoğlu A
      . Early aggressive parenteral nutrition induced high insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP3) levels can prevent risk of retinopathy of prematurity. Iran J Pediatr. 2013;23(4):403–410pmid:24427493
      OpenUrlPubMed
      1. Vlaardingerbroek H,
      2. Vermeulen MJ,
      3. Rook D, et al.
      Safety and efficacy of early parenteral lipid and high-dose amino acid administration to very low birth weight infants. J Pediatr. 2013;163(3):638–644.e5.
      OpenUrlCrossRefPubMedWeb of Science
      1. Hanson C,
      2. Sundermeier J,
      3. Dugick L,
      4. Lyden E,
      5. Anderson-Berry AL
      . Implementation, process, and outcomes of nutrition best practices for infants <1500 g. Nutr Clin Pract. 2011;26(5):614–624pmid:21947645
      OpenUrlAbstract/FREE Full Text
    29. ↵
      1. Drenckpohl D,
      2. McConnell C,
      3. Gaffney S,
      4. Niehaus M,
      5. Macwan KS
      . Randomized trial of very low birth weight infants receiving higher rates of infusion of intravenous fat emulsions during the first week of life. Pediatrics. 2008;122(4):743–751pmid:18829797
      OpenUrlAbstract/FREE Full Text
    30. ↵
      1. Beken S,
      2. Dilli D,
      3. Fettah ND,
      4. Kabataş EU,
      5. Zenciroğlu A,
      6. Okumuş N
      . The influence of fish-oil lipid emulsions on retinopathy of prematurity in very low birth weight infants: a randomized controlled trial. Early Hum Dev. 2014;90(1):27–31pmid:24314586
      OpenUrlCrossRefPubMed
    31. ↵
      1. Pawlik D,
      2. Lauterbach R,
      3. Turyk E
      . Fish-oil fat emulsion supplementation may reduce the risk of severe retinopathy in VLBW infants. Pediatrics. 2011;127(2):223–228pmid:21199856
      OpenUrlAbstract/FREE Full Text
    32. ↵
      1. Mactier H,
      2. McCulloch DL,
      3. Hamilton R, et al.
      Vitamin A supplementation improves retinal function in infants at risk of retinopathy of prematurity. J Pediatr. 2012;160(6):954–959e1
      OpenUrlCrossRefPubMed
      1. Wardle SP,
      2. Hughes A,
      3. Chen S,
      4. Shaw NJ
      . Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2001;84(1):F9–F13pmid:11124916
      OpenUrlAbstract/FREE Full Text
    34. ↵
      1. Shenai JP,
      2. Kennedy KA,
      3. Chytil F,
      4. Stahlman MT
      . Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr. 1987;111(2):269–277pmid:3302193
      OpenUrlCrossRefPubMedWeb of Science
    35. ↵
      1. Uberos J,
      2. Miras-Baldo M,
      3. Jerez-Calero A,
      4. Narbona-López E
      . Effectiveness of vitamin a in the prevention of complications of prematurity. Pediatr Neonatol. 2014;55(5):358–362pmid:24582166
      OpenUrlCrossRefPubMed
    36. ↵
      1. Johnson L,
      2. Quinn GE,
      3. Abbasi S, et al
      . Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: a controlled clinical trial. J Pediatr. 1989;114(5):827–838pmid:2654350
      OpenUrlCrossRefPubMedWeb of Science
    37. ↵
      1. Phelps DL,
      2. Rosenbaum AL,
      3. Isenberg SJ,
      4. Leake RD,
      5. Dorey FJ
      . Tocopherol efficacy and safety for preventing retinopathy of prematurity: a randomized, controlled, double-masked trial. Pediatrics. 1987;79(4):489–500pmid:3547300
      OpenUrlAbstract/FREE Full Text
      1. Speer ME,
      2. Blifeld C,
      3. Rudolph AJ,
      4. Chadda P,
      5. Holbein ME,
      6. Hittner HM
      . Intraventricular hemorrhage and vitamin E in the very low-birth-weight infant: evidence for efficacy of early intramuscular vitamin E administration. Pediatrics. 1984;74(6):1107–1112pmid:6504632
      OpenUrlAbstract/FREE Full Text
    39. ↵
      1. Finer NN,
      2. Schindler RF,
      3. Peters KL,
      4. Grant GD
      . Vitamin E and retrolental fibroplasia. Improved visual outcome with early vitamin E. Ophthalmology. 1983;90(5):428–435pmid:6348635
      OpenUrlCrossRefPubMed
    40. ↵
      1. Hittner HM,
      2. Godio LB,
      3. Speer ME, et al
      . Retrolental fibroplasia: further clinical evidence and ultrastructural support for efficacy of vitamin E in the preterm infant. Pediatrics. 1983;71(3):423–432pmid:6687494
      OpenUrlAbstract/FREE Full Text
      1. Finer NN,
      2. Schindler RF,
      3. Grant G,
      4. Hill GB,
      5. Peters K
      . Effect of intramuscular vitamin E on frequency and severity of retrolental fibroplasia. A controlled trial. Lancet. 1982;1(8281):1087–1091pmid:6122890
      OpenUrlCrossRefPubMedWeb of Science
      1. Puklin JE,
      2. Simon RM,
      3. Ehrenkranz RA
      . Influence on retrolental fibroplasia of intramuscular vitamin E administration during respiratory distress syndrome. Ophthalmology. 1982;89(2):96–103pmid:7041039
      OpenUrlCrossRefPubMedWeb of Science
    43. ↵
      1. Hittner HM,
      2. Godio LB,
      3. Rudolph AJ, et al
      . Retrolental fibroplasia: efficacy of vitamin E in a double-blind clinical study of preterm infants. N Engl J Med. 1981;305(23):1365–1371pmid:7029275
      OpenUrlCrossRefPubMedWeb of Science
    44. ↵
      1. Friedman CA,
      2. McVey J,
      3. Borne MJ, et al
      . Relationship between serum inositol concentration and development of retinopathy of prematurity: a prospective study. J Pediatr Ophthalmol Strabismus. 2000;37(2):79–86pmid:10779265
      OpenUrlPubMedWeb of Science
    45. ↵
      1. Hallman M,
      2. Bry K,
      3. Hoppu K,
      4. Lappi M,
      5. Pohjavuori M
      . Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med. 1992;326(19):1233–1239pmid:1560798
      OpenUrlCrossRefPubMedWeb of Science
    46. ↵
      1. Manzoni P,
      2. Guardione R,
      3. Bonetti P, et al
      . Lutein and zeaxanthin supplementation in preterm very low-birth-weight neonates in neonatal intensive care units: a multicenter randomized controlled trial. Am J Perinatol. 2013;30(1):25–32pmid:22773282
      OpenUrlPubMed
    47. ↵
      1. Romagnoli C,
      2. Giannantonio C,
      3. Cota F, et al
      . A prospective, randomized, double blind study comparing lutein to placebo for reducing occurrence and severity of retinopathy of prematurity. J Matern Fetal Neonatal Med. 2011;24(suppl 1):147–150pmid:21942614
      OpenUrlCrossRefPubMedWeb of Science
    48. ↵
      1. Schmidt B,
      2. Whyte RK,
      3. Asztalos EV, et al; Canadian Oxygen Trial (COT) Group
      . Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial. JAMA. 2013;309(20):2111–2120pmid:23644995
      OpenUrlCrossRefPubMedWeb of Science
    49. ↵
      1. Urrets-Zavalia JA,
      2. Crim N,
      3. Knoll EG, et al
      . Impact of changing oxygenation policies on retinopathy of prematurity in a neonatal unit in Argentina. Br J Ophthalmol. 2012;96(12):1456–1461pmid:23038764
      OpenUrlAbstract/FREE Full Text
    50. ↵
      1. Tlucek PS,
      2. Grace SF,
      3. Anderson MP,
      4. Siatkowski RM
      . Effect of the oxygen saturation target on clinical characteristics of early- versus late-onset retinopathy of prematurity. J AAPOS. 2012;16(1):70–74
      OpenUrlCrossRefPubMed
    51. ↵
      1. Castillo A,
      2. Deulofeut R,
      3. Critz A,
      4. Sola A
      . Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO₂technology. Acta Paediatr. 2011;100(2):188–192pmid:20825604
      OpenUrlCrossRefPubMed
    52. ↵
      1. Tlucek PS,
      2. Corff KE,
      3. Bright BC,
      4. Bedwell SM,
      5. Sekar KC,
      6. Siatkowski RM
      . Effect of decreasing target oxygen saturation on retinopathy of prematurity. J AAPOS. 2010;14(5):406–411pmid:21035066
      OpenUrlCrossRefPubMed
    53. ↵
      1. Carlo WA,
      2. Finer NN,
      3. Walsh MC, et al; SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network
      . Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362(21):1959–1969pmid:20472937
      OpenUrlCrossRefPubMedWeb of Science
    54. ↵
      1. Tokuhiro Y,
      2. Yoshida T,
      3. Nakabayashi Y, et al.
      Reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity in infants of <33 weeks gestation. Pediatr Int. 2009;51(6):804–806
      OpenUrlCrossRefPubMed
    55. ↵
      1. Noori S,
      2. Patel D,
      3. Friedlich P,
      4. Siassi B,
      5. Seri I,
      6. Ramanathan R
      . Effects of low oxygen saturation limits on the ductus arteriosus in extremely low birth weight infants. J Perinatol. 2009;29(8):553–557
      OpenUrlCrossRefPubMedWeb of Science
    56. ↵
      1. Sears JE,
      2. Pietz J,
      3. Sonnie C,
      4. Dolcini D,
      5. Hoppe G
      . A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology. 2009;116(3):513–518pmid:19157560
      OpenUrlCrossRefPubMedWeb of Science
    57. ↵
      1. Deulofeut R,
      2. Dudell G,
      3. Sola A
      . Treatment-by-gender effect when aiming to avoid hyperoxia in preterm infants in the NICU. Acta Paediatr. 2007;96(7):990–994pmid:17577339
      OpenUrlCrossRefPubMedWeb of Science
    58. ↵
      1. Wallace DK,
      2. Veness-Meehan KA,
      3. Miller WC
      . Incidence of severe retinopathy of prematurity before and after a modest reduction in target oxygen saturation levels. J AAPOS. 2007;11(2):170–174pmid:17416327
      OpenUrlCrossRefPubMed
      1. Wright KW,
      2. Sami D,
      3. Thompson L,
      4. Ramanathan R,
      5. Joseph R,
      6. Farzavandi S
      . A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity. Trans Am Ophthalmol Soc. 2006;104:78–84pmid:17471328
      OpenUrlPubMed
    60. ↵
      1. Vanderveen DK,
      2. Mansfield TA,
      3. Eichenwald EC
      . Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. J AAPOS. 2006;10(5):445–448pmid:17070480
      OpenUrlCrossRefPubMedWeb of Science
    61. ↵
      1. Deulofeut R,
      2. Critz A,
      3. Adams-Chapman I,
      4. Sola A
      . Avoiding hyperoxia in infants < or = 1250 g is associated with improved short- and long-term outcomes. J Perinatol. 2006;26(11):700–705pmid:17036032
      OpenUrlCrossRefPubMedWeb of Science
    62. ↵
      1. Tin W,
      2. Milligan DW,
      3. Pennefather P,
      4. Hey E
      . Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed. 2001;84(2):F106–F110pmid:11207226
      OpenUrlAbstract/FREE Full Text
    63. ↵
      1. Di Fiore JM,
      2. Walsh M,
      3. Wrage L, et al; SUPPORT Study Group of Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
      . Low oxygen saturation target range is associated with increased incidence of intermittent hypoxemia. J Pediatr. 2012;161(6):1047–1052pmid:22738947
      OpenUrlCrossRefPubMedWeb of Science
    64. ↵
      1. Stenson BJ,
      2. Tarnow-Mordi WO,
      3. Darlow BA, et al; BOOST II United Kingdom Collaborative Group; BOOST II Australia Collaborative Group; BOOST II New Zealand Collaborative Group
      . Oxygen saturation and outcomes in preterm infants. N Engl J Med. 2013;368(22):2094–2104pmid:23642047
      OpenUrlCrossRefPubMedWeb of Science
    65. ↵
      1. Chen HL,
      2. Tseng HI,
      3. Lu CC,
      4. Yang SN,
      5. Fan HC,
      6. Yang RC
      . Effect of blood transfusions on the outcome of very low body weight preterm infants under two different transfusion criteria. Pediatr Neonatol. 2009;50(3):110–116pmid:19579757
      OpenUrlCrossRefPubMedWeb of Science
      1. Bell EF,
      2. Strauss RG,
      3. Widness JA, et al
      . Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. Pediatrics. 2005;115(6):1685–1691pmid:15930233
      OpenUrlAbstract/FREE Full Text
      1. Brooks SE,
      2. Marcus DM,
      3. Gillis D,
      4. Pirie E,
      5. Johnson MH,
      6. Bhatia J
      . The effect of blood transfusion protocol on retinopathy of prematurity: A prospective, randomized study. Pediatrics. 1999;104(3 pt 1):514–518pmid:10469778
      OpenUrlAbstract/FREE Full Text
    68. ↵
      1. Kirpalani H,
      2. Whyte RK,
      3. Andersen C, et al
      . The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr. 2006;149(3):301–307pmid:16939737
      OpenUrlCrossRefPubMedWeb of Science
    69. ↵
      1. Ohls RK,
      2. Christensen RD,
      3. Kamath-Rayne BD, et al
      . A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants. Pediatrics. 2013;132(1). Available at: www.pediatrics.org/cgi/content/full/132/1/e119pmid:23776118
      1. Schneider JK,
      2. Gardner DK,
      3. Cordero L
      . Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants. Pharmacotherapy. 2008;28(11):1335–1340pmid:18956993
      OpenUrlCrossRefPubMed
      1. Fauchère JC,
      2. Dame C,
      3. Vonthein R, et al
      . An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008;122(2):375–382pmid:18676556
      OpenUrlAbstract/FREE Full Text
      1. Türker G,
      2. Sarper N,
      3. Gökalp AS,
      4. Usluer H
      . The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants. Am J Perinatol. 2005;22(8):449–455pmid:16283605
      OpenUrlCrossRefPubMed
      1. Romagnoli C,
      2. Zecca E,
      3. Gallini F,
      4. Girlando P,
      5. Zuppa AA
      . Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity? Eur J Pediatr. 2000;159(8):627–628pmid:10968244
      OpenUrlCrossRefPubMedWeb of Science
      1. Al-Kharfy T,
      2. Smyth JA,
      3. Wadsworth L, et al
      . Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions. J Pediatr. 1996;129(1):89–96pmid:8757567
      OpenUrlCrossRefPubMedWeb of Science
      1. Arif B,
      2. Ferhan K
      . Recombinant human erythropoietin therapy in low-birthweight preterm infants: a prospective controlled study. Pediatr Int. 2005;47(1):67–71pmid:15693870
      OpenUrlCrossRefPubMed
      1. Carnielli VP,
      2. Da Riol R,
      3. Montini G
      . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998;79(1):F44–F48pmid:9797624
      OpenUrlAbstract/FREE Full Text
      1. Maier RF,
      2. Obladen M,
      3. Müller-Hansen I, et al; European Multicenter Erythropoietin Beta Study Group
      . Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr. 2002;141(1):8–15pmid:12091844
      OpenUrlCrossRefPubMedWeb of Science
      1. Maier RF,
      2. Obladen M,
      3. Scigalla P, et al; European Multicentre Erythropoietin Study Group
      . The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N Engl J Med. 1994;330(17):1173–1178pmid:8139627
      OpenUrlCrossRefPubMedWeb of Science
      1. Ohls RK,
      2. Ehrenkranz RA,
      3. Wright LL, et al
      . Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics. 2001;108(4):934–942pmid:11581447
      OpenUrlAbstract/FREE Full Text
      1. Shannon KM,
      2. Keith JF III,
      3. Mentzer WC, et al
      . Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics. 1995;95(1):1–8pmid:7770284
      OpenUrlAbstract/FREE Full Text
    81. ↵
      1. Yeo CL,
      2. Choo S,
      3. Ho LY
      . Effect of recombinant human erythropoietin on transfusion needs in preterm infants. J Paediatr Child Health. 2001;37(4):352–358pmid:11532054
      OpenUrlCrossRefPubMed
    82. ↵
      1. Benjamin DK Jr,
      2. Hudak ML,
      3. Duara S, et al; Fluconazole Prophylaxis Study Team
      . Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. JAMA. 2014;311(17):1742–1749pmid:24794367
      OpenUrlCrossRefPubMedWeb of Science
      1. Kaufman D,
      2. Boyle R,
      3. Hazen KC,
      4. Patrie JT,
      5. Robinson M,
      6. Donowitz LG
      . Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345(23):1660–1666pmid:11759644
      OpenUrlCrossRefPubMedWeb of Science
      1. Manzoni P,
      2. Stolfi I,
      3. Pugni L, et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections; Italian Society of Neonatology
      . A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356(24):2483–2495pmid:17568029
      OpenUrlCrossRefPubMedWeb of Science
      1. Aydemir C,
      2. Oguz SS,
      3. Dizdar EA, et al
      . Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed. 2011;96(3):F164–F168pmid:20659937
      OpenUrlAbstract/FREE Full Text
    86. ↵
      1. Cetinkaya M,
      2. Ercan TE,
      3. Saglam OK,
      4. Buyukkale G,
      5. Kavuncuoglu S,
      6. Mete F
      . Efficacy of prophylactic fluconazole therapy in decreasing the incidence of Candida infections in extremely low birth weight preterm infants. Am J Perinatol. 2014;31(12):1043–1048pmid:24584998
      OpenUrlCrossRefPubMed
    87. ↵
      1. Johannes C,
      2. Dow K
      . Does reducing light exposure decrease the incidence of retinopathy of prematurity in premature infants? Paediatr Child Health. 2013;18(6):298–300pmid:24421696
      OpenUrlPubMed
      1. Qureshi MJ,
      2. Kumar M
      . D-Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev. September 2013;9:CD001073pmid:24002688
      OpenUrlPubMed
    89. ↵
      1. Raju TN,
      2. Langenberg P,
      3. Bhutani V,
      4. Quinn GE
      . Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr. 1997;131(6):844–850pmid:9427888
      OpenUrlCrossRefPubMedWeb of Science
    90. ↵
      1. Bulbul A,
      2. Okan F,
      3. Bulbul L,
      4. Nuhoglu A
      . Effect of low versus high early parenteral nutrition on plasma amino acid profiles in very low birth-weight infants. J Matern Fetal Neonatal Med. 2012;25(6):770–776pmid:21770835
      OpenUrlCrossRefPubMedWeb of Science
      1. Kotsopoulos K,
      2. Benadiba-Torch A,
      3. Cuddy A,
      4. Shah PS
      . Safety and efficacy of early amino acids in preterm <28 weeks gestation: prospective observational comparison. J Perinatol. 2006;26(12):749–754pmid:17024139
      OpenUrlCrossRefPubMedWeb of Science
    92. ↵
      1. Thureen PJ,
      2. Melara D,
      3. Fennessey PV,
      4. Hay WW Jr
      . Effect of low versus high intravenous amino acid intake on very low birth weight infants in the early neonatal period. Pediatr Res. 2003;53(1):24–32pmid:12508078
      OpenUrlCrossRefPubMedWeb of Science
    93. ↵
      1. Brion LP,
      2. Bell EF,
      3. Raghuveer TS
      . Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2003; (4):CD003665pmid:14583988
      OpenUrlPubMed
    94. ↵
      1. Brown LD,
      2. Cheung A,
      3. Harwood JE,
      4. Battaglia FC
      . Inositol and mannose utilization rates in term and late-preterm infants exceed nutritional intakes. J Nutr. 2009;139(9):1648–1652pmid:19494026
      OpenUrlAbstract/FREE Full Text
    95. ↵
      1. Cavalli C,
      2. Teng C,
      3. Battaglia FC,
      4. Bevilacqua G
      . Free sugar and sugar alcohol concentrations in human breast milk. J Pediatr Gastroenterol Nutr. 2006;42(2):215–221pmid:16456418
      OpenUrlCrossRefPubMed
    96. ↵
      Enfamil Premature. Mead Johnson Nutrition. Available at: www.enfamil.com/products/special-dietary-needs/enfamil-premature. Accessed July, 23, 2015
    97. Similac Special Care 24 with Iron. Abbott Laboratories. Available at: http://abbottnutrition.com/brands/products/similac-special-care-24-with-iron. Accessed July, 23, 2015
    98. ↵
      Gerber Good Start Premature 24. Société des Produits Nestlé. Available at: http://medical.gerber.com/products/formulas/good-start-premature-24. Accessed July, 23, 2015
    99. ↵
      1. Eunice Kennedy Shriver National Institute of Child Health and Human Development
      . Inositol to Reduce Retinopathy of Prematurity (INS-3). Available at: https://clinicaltrials.gov/show/NCT01954082NLM identifier: NCT01954082. Accessed July 23, 2015
    100. ↵
      1. Whyte R,
      2. Kirpalani H
      . Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane Database Syst Rev. 2011; (11):CD000512pmid:22071798
      OpenUrlPubMed
      1. Ohlsson A,
      2. Aher SM
      . Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. April 2014;4:CD004863pmid:24771408
      OpenUrlPubMed
    102. ↵
      1. Aher SM,
      2. Ohlsson A
      . Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. April 2014;4:CD004868pmid:24760628
    103. ↵
      1. DeJonge M,
      2. Burchfield D,
      3. Bloom B, et al
      . Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr. 2007;151(3):260–265.e1pmid:17719934
      OpenUrlCrossRefPubMedWeb of Science
      1. Bertini G,
      2. Elia S,
      3. Ceciarini F,
      4. Dani C
      . Reduction of catheter-related bloodstream infections in preterm infants by the use of catheters with the AgION antimicrobial system. Early Hum Dev. 2013;89(1):21–25pmid:22841551
      OpenUrlCrossRefPubMed
    105. ↵
      1. Payne NR,
      2. Barry J,
      3. Berg W, et al; Stop Transmission of Pathogens (STOP) team of the St. Paul Campus; Prevent Infection Team (PIT) of the Minneapolis Campus of Children’s Hospitals and Clinics of Minnesota
      . Sustained reduction in neonatal nosocomial infections through quality improvement efforts. Pediatrics. 2012;129(1). Available at: www.pediatrics.org/cgi/content/full/129/1/e165pmid:22144702
    106. ↵
      1. Martin JA,
      2. Hamilton BE,
      3. Osterman MJ,
      4. Curtin SC,
      5. Matthews TJ
      . Births: Final data for 2013. Natl Vital Stat Rep. 2015;64(1):1–65pmid:25603115
      OpenUrlPubMed
    View Abstract

     

    View this article with LENS
    Email

    Alerts
    Citation Tools
    Interventions To Prevent Retinopathy of Prematurity: A Meta-analysis
    Jennifer L. Fang, Atsushi Sorita, William A. Carey, Christopher E. Colby, M. Hassan Murad, Fares Alahdab
    Pediatrics Apr 2016, 137 (4) e20153387; DOI: 10.1542/peds.2015-3387
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Print
    PDF
    Insight Alerts

    Subjects

    Back to top